β-Lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain)

被引:42
作者
Sabaté, M [1 ]
Miró, E [1 ]
Navarro, F [1 ]
Vergés, C [1 ]
Aliaga, R [1 ]
Mirelis, B [1 ]
Prats, G [1 ]
机构
[1] Univ Autonoma Barcelona, Dept Microbiol, Hosp Santa Creu & Sant Pau, Barcelona 08025, Spain
关键词
D O I
10.1093/jac/dkf057
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to evaluate the incidence of decreased susceptibility to broad-spectrum cephalosporins in Enterobacteriaceae that lack inducible chromosomal bla genes, and to determine the enzymes responsible for resistance. From all clinically relevant Enterobacteriaceae strains isolated between 1994 and 1996, 88 of 7054 Escherichia coli, seven of 581 Klebsiella pneumoniae and 23 of 166 Klebsiella oxytoca strains were studied because of their decreased susceptibilities to broad-spectrum cephalosporins (as reflected in intermediate susceptibilities and/or positive synergy tests and/or irregular crenellated inhibition zones). The most frequent mechanism implicated in decreased susceptibility to broad-spectrum cephalosporins displayed by E. coli and K. oxytoca was hyperproduction of chromosomal beta-lactamase, followed by plasmid-mediated SHV-1 hyperproduction in E. coli. In our hospital, the incidence of plasmid-mediated extended-spectrum beta-lactamases (ESBLs) between 1994 and 1996 was low. ESBLs were found in only 10 (0.14%) E. coli strains (six CTX-M-9, two TEM-12 and two SHV-2), in one (0.17%) K. pneumoniae strain (SHV-2) and in no K. oxytoca strains. The relatively wide variety of beta-lactamases that were detected among these common bacteria isolated from a single medical centre, including non-TEM- and non-SHV-derived ESBLs, appears epidemiologically remarkable.
引用
收藏
页码:989 / 997
页数:9
相关论文
共 57 条
[41]   Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction [J].
Miró, E ;
del Cuerpo, M ;
Navarro, F ;
Sabaté, P ;
Mirelis, B ;
Prats, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :535-538
[42]  
National Committee for Clinical Laboratory Standards, 1995, M100S6 NCCLS
[43]   CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999-December 2000) [J].
Navarro, F ;
Perez-Trallero, E ;
Marimon, JM ;
Aliaga, R ;
Gomariz, M ;
Mirelis, B .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (03) :383-389
[44]   Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli [J].
Nelson, EC ;
Elisha, BG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :957-959
[45]   Detection of genes coding for extended-spectrum SHV beta-lactamases in clinical isolates by a molecular genetic method, and comparison with the E test [J].
NueschInderbinen, MT ;
Hachler, H ;
Kayser, FH .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (05) :398-402
[46]   NOVEL PLASMID-MEDIATED BETA-LACTAMASE (MIR-1) CONFERRING RESISTANCE TO OXYIMINO-LACTAMS AND ALPHA-METHOXY BETA-LACTAMS IN CLINICAL ISOLATES OF KLEBSIELLA-PNEUMONIAE [J].
PAPANICOLAOU, GA ;
MEDEIROS, AA ;
JACOBY, GA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (11) :2200-2209
[47]   DOES HIGH-LEVEL PRODUCTION OF SHV-TYPE PENICILLINASE CONFER RESISTANCE TO CEFTAZIDIME IN ENTEROBACTERIACEAE [J].
PETIT, A ;
BENYAGHLANEBOUSLAMA, H ;
SOFER, L ;
LABIA, R .
FEMS MICROBIOLOGY LETTERS, 1992, 92 (01) :89-94
[48]   Prevalence and mechanism of resistance to 'third-generation' cephalosporins in clinically relevant isolates of Enterobacteriaceae from 43 hospitals in the UK, 1990-1991 [J].
Piddock, LJV ;
Walters, RN ;
Jin, YF ;
Turner, HL ;
GascoyneBinzi, DM ;
Hawkey, PM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (02) :177-187
[49]   A SURVEY OF BETA-LACTAMASES FROM 618 ISOLATES OF KLEBSIELLA SPP [J].
REIG, R ;
ROY, C ;
HERMIDA, M ;
TERUEL, D ;
COIRA, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (01) :29-35
[50]   High-level expression of chromosomally encoded SHV-1 β-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae [J].
Rice, LB ;
Carias, LL ;
Hujer, AM ;
Bonafede, M ;
Hutton, R ;
Hoyen, C ;
Bonomo, RA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :362-367